- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01787877
Inflammatory Biomarkers as Tool in Diagnosis and Management of Patients With Ischemic Stroke
Inflammatory Biomarkers as Additional Tool to Neuroimaging in the Diagnosis and Management of Patients With Ischemic Stroke
Stroke represents the third commonest cause of death after heart disease and all types of cancer combined, and is the leading cause of long-term permanent disability among adults. Recombinant tissue plasminogen activator (tPA) is currently the only safe medical treatment for acute ischemic stroke but only a small fraction of patients are eligible for a thrombolysis treatment. Current guidelines on thrombolysis post stroke with tPA exclude its uses beyond 3 hours after stroke onset and when time of onset is unknown thus excluding many patients from potentially beneficial treatment.
For an appropriate triage and management of patients, it is essential to improve imaging techniques beyond a simple CT scan. Perfusion computed tomography (PCT), currently considered as an investigational technique, permits a quantitative determination of the cerebral perfusion within the brain. It helps distinguish salvageable ischemic penumbra from irreversibly infarcted core in acute stroke patients. This technique has therefore the potential to select patients who are most likely to benefit from thrombolysis with tPA, can be used to predict the benefit after thrombolysis and determine the suitability for other therapeutic interventions. In patients with a primary diagnosis of TIA, PCT would help to identify possible persistent cerebral ischemia but also provide important information for rapid instigation of prophylactic strategies.
The diagnosis and management of patients with ischemic stroke and TIA is challenging and is primarily based on clinical assessment in conjunction with neuroimaging. Development of specific molecular biomarkers as additional tools to support a clinical diagnosis, exclude common stroke mimics such as migraine or epileptic seizures, identify patients at risk of disease, and help guide patient treatment by predicting complications following t-PA treatment would be of great value.
Study Overview
Status
Conditions
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Saad Abu Saleh, MD
- Phone Number: +972508434152
- Email: saad.a@ziv.health.gov.il
Study Contact Backup
- Name: Karine Beiruti, PhD
- Phone Number: +97246828208
- Email: karine.b@ziv.health.gov.il
Study Locations
-
-
-
Safed, Israel, 13000
- ZIV Medical Center
-
Contact:
- Radi Shahien, MD
- Phone Number: +972508438927
- Email: radi.s@ziv.health.gov.il
-
Sub-Investigator:
- Radi Shahien, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Ability to provide written informed consent and to be compliant with the schedule of protocol assessments
- Diagnosis of acute clinical stroke
- Ages 18 and above inclusive
- Both genders eligible for the study
Exclusion Criteria:
- Intracerebral hemorrhage according to Computed Tomography (CT)
- Clinical signs of infection on admission
- Patients with chronic inflammatory disease
- Hematologic disorders (anemia)
- Malignant tumor
- Renal or hepatic failure
- Treatment with anti-inflammatory or corticosteroids drugs within a month before stroke
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
Stroke patients reporting to the ER
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relationship between inflammatory biomarkers and CVA patients
Time Frame: Follow-up 1 year
|
To assess the levels over the time of selected inflammatory biomarkers, to determine the relationship between them after acute ischemic stroke and to evaluate their correlation with patients characteristics
|
Follow-up 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Identify patients at risk of recurrent stroke by identifying molecular biomarkers
Time Frame: Follow-up for 1 year
|
To develop specific molecular biomarkers to support the clinical diagnosis, identify patients at risk of recurrent stroke and select the appropriate treatment
|
Follow-up for 1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Saad Abu Saleh, MD, ZIV Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0064-12-ZIV
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cerebrovascular Accident
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Heart and Stroke Foundation...CompletedStroke | Vascular Accident, Brain | Stroke, Acute | Cerebrovascular Accident | Cerebral Stroke | Cerebrovascular Stroke | Cerebrovascular Accident, Acute | Apoplexy | CVA | Cerebrovascular ApoplexyCanada
-
Sheba Medical CenterCompletedLate Effects of Cerebrovascular Accident
-
Universitaire Ziekenhuizen KU LeuvenCompletedTranscranial Direct Current Stimulation | Cerebrovascular Accident (CVA)Belgium
-
Sunnyview Rehabilitation HospitalRecruitingStroke | Stroke, Acute | Cerebrovascular Accident | Cerebrovascular Accident, AcuteUnited States
-
Peking University Third HospitalAstraZeneca Investment (China) Co., LtdCompletedCerebrovascular Accident | Cerebrovascular Accident, AcuteChina
-
Medical University of South CarolinaIcahn School of Medicine at Mount SinaiCompletedIschemic Cerebrovascular AccidentUnited States
-
John DavidsonWashington University School of MedicineWithdrawnIschemic Cerebrovascular AccidentUnited States
-
University of California, IrvineEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingStroke, Ischemic | Cerebrovascular Accident (CVA)United States
-
Parker Hannifin CorporationCedars-Sinai Medical Center; Kessler Foundation; TIRR Memorial Hermann; Shirley... and other collaboratorsCompletedStroke | Hemiplegia | Cerebrovascular Accident (CVA)United States
-
University Hospital, Strasbourg, FranceRecruitingCerebrovascular Accident (CVA)France